2021
Case fatality risk of the SARS-CoV-2 variant of concern B.1.1.7 in England, 16 November to 5 February
Grint D, Wing K, Williamson E, McDonald H, Bhaskaran K, Evans D, Evans S, Walker A, Hickman G, Nightingale E, Schultze A, Rentsch C, Bates C, Cockburn J, Curtis H, Morton C, Bacon S, Davy S, Wong A, Mehrkar A, Tomlinson L, Douglas I, Mathur R, Blomquist P, MacKenna B, Ingelsby P, Croker R, Parry J, Hester F, Harper S, DeVito N, Hulme W, Tazare J, Goldacre B, Smeeth L, Eggo R. Case fatality risk of the SARS-CoV-2 variant of concern B.1.1.7 in England, 16 November to 5 February. Eurosurveillance 2021, 26: 2100256. PMID: 33739254, PMCID: PMC7976383, DOI: 10.2807/1560-7917.es.2021.26.11.2100256.Peer-Reviewed Original ResearchEarly initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study
Rentsch CT, Beckman JA, Tomlinson L, Gellad WF, Alcorn C, Kidwai-Khan F, Skanderson M, Brittain E, King JT, Ho YL, Eden S, Kundu S, Lann MF, Greevy RA, Ho PM, Heidenreich PA, Jacobson DA, Douglas IJ, Tate JP, Evans SJW, Atkins D, Justice AC, Freiberg MS. Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study. The BMJ 2021, 372: n311. PMID: 33574135, PMCID: PMC7876672, DOI: 10.1136/bmj.n311.Peer-Reviewed Original ResearchConceptsProphylactic anticoagulationDay mortalityEarly initiationTherapeutic anticoagulationCohort studyInpatient mortalityHospital admissionAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionCoronavirus disease 2019 (COVID-19) mortalitySyndrome coronavirus 2 infectionCOVID-19History of anticoagulationSerious bleeding eventsCoronavirus 2 infectionHours of admissionObservational cohort studyRisk of deathCoronavirus disease 2019Real-world evidenceBleeding eventsSubcutaneous heparinHospital stayNationwide cohortCumulative incidenceUse of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts
Wong AY, MacKenna B, Morton CE, Schultze A, Walker AJ, Bhaskaran K, Brown JP, Rentsch CT, Williamson E, Drysdale H, Croker R, Bacon S, Hulme W, Bates C, Curtis HJ, Mehrkar A, Evans D, Inglesby P, Cockburn J, McDonald HI, Tomlinson L, Mathur R, Wing K, Forbes H, Eggo RM, Parry J, Hester F, Harper S, Evans SJ, Smeeth L, Douglas IJ, Goldacre B, Collaborative T. Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts. Annals Of The Rheumatic Diseases 2021, 80: 943-951. PMID: 33478953, PMCID: PMC7823433, DOI: 10.1136/annrheumdis-2020-219517.Peer-Reviewed Original ResearchConceptsNon-steroidal anti-inflammatory drugsPrescribed non-steroidal anti-inflammatory drugsRheumatoid arthritis/osteoarthritisArthritis/osteoarthritisCurrent NSAID usersMultivariable-adjusted modelsAnti-inflammatory drugsNSAID prescriptionsNSAID usersGeneral populationCOVID-19Risk of deathNational Health Service EnglandRoutine therapeutic useRoutine clinical dataCohort studyCurrent useCox regressionClinical dataCohort analysisLower riskEvidence of differencesDeath dataTherapeutic useDeath
2020
HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform
Bhaskaran K, Rentsch CT, MacKenna B, Schultze A, Mehrkar A, Bates CJ, Eggo RM, Morton CE, Bacon SCJ, Inglesby P, Douglas IJ, Walker AJ, McDonald HI, Cockburn J, Williamson EJ, Evans D, Forbes HJ, Curtis HJ, Hulme WJ, Parry J, Hester F, Harper S, Evans SJW, Smeeth L, Goldacre B. HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform. The Lancet HIV 2020, 8: e24-e32. PMID: 33316211, PMCID: PMC7773630, DOI: 10.1016/s2352-3018(20)30305-2.Peer-Reviewed Original ResearchConceptsCOVID-19 deathsNational death registrationsPrimary care dataHazard ratioHIV infectionOpenSAFELY platformBlack ethnicityHealth Research Oxford Biomedical Research CentreElectronic primary care dataPopulation-based cohort analysisDeath registrationUK primary care dataCare dataLarge-scale population-based studyRetrospective cohort studyPrimary care recordsUK Medical Research CouncilPopulation-based studyRisk of deathHealth Data Research UKNon-black individualsNational InstituteCOVID-19 mortalityMedical Research CouncilBiomedical Research CentreRisk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform
Schultze A, Walker AJ, MacKenna B, Morton CE, Bhaskaran K, Brown JP, Rentsch CT, Williamson E, Drysdale H, Croker R, Bacon S, Hulme W, Bates C, Curtis HJ, Mehrkar A, Evans D, Inglesby P, Cockburn J, McDonald HI, Tomlinson L, Mathur R, Wing K, Wong AYS, Forbes H, Parry J, Hester F, Harper S, Evans SJW, Quint J, Smeeth L, Douglas IJ, Goldacre B, Collaborative O. Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform. The Lancet Respiratory Medicine 2020, 8: 1106-1120. PMID: 32979987, PMCID: PMC7515601, DOI: 10.1016/s2213-2600(20)30415-x.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, InhalationAdolescentAdrenal Cortex HormonesAdultAgedAged, 80 and overAsthmaBetacoronavirusCohort StudiesCoronavirus InfectionsCOVID-19Electronic Health RecordsEnglandFemaleHumansMaleMiddle AgedMuscarinic AntagonistsPandemicsPneumonia, ViralProportional Hazards ModelsPulmonary Disease, Chronic ObstructiveRegression AnalysisSARS-CoV-2Young AdultConceptsChronic obstructive pulmonary diseaseCOVID-19-related deathsIndex dateObstructive pulmonary diseaseElectronic health recordsOpenSAFELY platformRespiratory medicationsCOPD cohortHazard ratioPulmonary diseaseAsthma cohortPrimary care electronic health recordsSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2High-dose ICSHigh-dose ICSsRegular ICS useΒ-agonistsObservational cohort studyUK Medical Research CouncilRisk of deathCox regression modelAcute respiratory diseaseSyndrome coronavirus 2